更正：标准剂量伊维菌素对重症 COVID-19 患者无效。
Correction: Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
作者信息
Camprubí Daniel, Almuedo-Riera Alex, Martí-Soler Helena, Soriano Alex, Hurtado Juan Carlos, Subirà Carme, Grau-Pujol Berta, Krolewiecki Alejandro, Muñoz Jose
出版信息
PLoS One. 2022 May 12;17(5):e0268667. doi: 10.1371/journal.pone.0268667. eCollection 2022.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0242184.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0242184。]
相似文献
1
Correction: Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.更正：标准剂量伊维菌素对重症 COVID-19 患者无效。
PLoS One. 2022 May 12;17(5):e0268667. doi: 10.1371/journal.pone.0268667. eCollection 2022.
2
Correction: Biting the bullet: When self-efficacy mediates the stressful effects of COVID-19 beliefs.更正：咬紧牙关：当自我效能感调节新冠疫情信念的压力效应时。
PLoS One. 2022 Mar 9;17(3):e0265330. doi: 10.1371/journal.pone.0265330. eCollection 2022.
3
Correction: Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia.更正：在捷克共和国，疫苗接种、加强针接种及既往感染对新冠病毒感染、住院或死亡的长期防护作用。
PLoS One. 2023 Nov 28;18(11):e0295159. doi: 10.1371/journal.pone.0295159. eCollection 2023.
4
Correction: Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated.更正：埃及患者新冠后症状的预测因素：新冠治疗中使用的药物被牵连。
PLoS One. 2022 Jul 5;17(7):e0271154. doi: 10.1371/journal.pone.0271154. eCollection 2022.
5
Correction: Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.更正：轻度和重度新冠病毒感染后针对严重急性呼吸综合征冠状病毒2的血清IgG反应及IgG无反应者分析
PLoS One. 2021 Oct 4;16(10):e0258401. doi: 10.1371/journal.pone.0258401. eCollection 2021.
6
Correction: Severe COVID-19 infection: An institutional review and literature overview.更正：重症新型冠状病毒肺炎感染：一项机构审查与文献综述。
PLoS One. 2024 Sep 6;19(9):e0310284. doi: 10.1371/journal.pone.0310284. eCollection 2024.
7
Correction: In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation.更正：墨西哥城一家三级医疗中心严重新型冠状病毒肺炎的院内死亡率；死亡原因、风险因素及医院饱和的影响
PLoS One. 2022 May 23;17(5):e0269053. doi: 10.1371/journal.pone.0269053. eCollection 2022.
8
Correction: Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.更正：干扰素（I型和III型）治疗COVID-19患者的临床疗效和安全性：一项随机对照试验的系统评价和荟萃分析。
PLoS One. 2023 Dec 15;18(12):e0296219. doi: 10.1371/journal.pone.0296219. eCollection 2023.
9
Correction: Proteinuria changes in kidney disease patients with clinical remission during the COVID-19 pandemic.更正：2019年冠状病毒病大流行期间临床缓解的肾病患者蛋白尿变化。
PLoS One. 2021 Aug 11;16(8):e0256255. doi: 10.1371/journal.pone.0256255. eCollection 2021.
10
Correction: Clinical characteristics of Egyptian male patients with COVID-19 acute respiratory distress syndrome.更正：埃及男性新冠肺炎急性呼吸窘迫综合征患者的临床特征
PLoS One. 2021 Oct 27;16(10):e0259432. doi: 10.1371/journal.pone.0259432. eCollection 2021.
引用本文的文献
1
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.伊维菌素：新冠疫情期间的一个争议焦点。
Life (Basel). 2022 Sep 6;12(9):1384. doi: 10.3390/life12091384.
本文引用的文献
1
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.标准剂量伊维菌素对重症 COVID-19 患者无效。
PLoS One. 2020 Nov 11;15(11):e0242184. doi: 10.1371/journal.pone.0242184. eCollection 2020.
Zotero 插件